Caroline Seymour

Debasish Tripathy, MD, provides perspective on some of the key data sets that were presented and published in 2021 in HER2-positive breast cancer.

Cristina Gasparetto, MD, shares pearls regarding treatment in frontline, early relapsed, and late relapsed multiple myeloma.

Aaron T. Gerds, MD, MS, discusses the use of TKIs, targeted agents, JAK inhibitors, and cellular therapy in hematologic malignancies.

Thomas C. Krivak, MD, discusses his approach to up-front treatment for women with newly diagnosed advanced ovarian cancer.

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.

The National Comprehensive Cancer Network is one of many organizations that is taking a stand against inequity in health care by aligning themselves with the new 3-year campaign, entitled “Close the Care Gap,” led by the Union for International Cancer Control.

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Sara A. Hurvitz, MD, reflects on the past year in HER2-positive breast cancer.

The Biden-Harris administration has announced a plan to restart the Cancer Moonshot initiative, which President Joe Biden first launched as vice president of the Obama administration in 2016.

Angela Jain, MD, provides perspective on use of PARP inhibitors in the treatment of patients with advanced ovarian cancer.

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

Sara A. Hurvitz, MD, provides perspective on key research that was presented during the 2021 SABCS in HER2-positive metastatic breast cancer.

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic cell transplant, indicating improvements in patient care overall.

Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.

The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.

Paying particular attention to the specific type of gene mutation on a molecular testing report is critical in an era of increasing genomic complexity in non–small cell lung cancer.

Naval Daver, MD, discusses the latest developments in acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and follicular lymphoma.

Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.

Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Chih-Yi (Andy) Liao, MD, discusses the focus of each presentation at the webinar, which centered on optimizing therapy in advanced pancreatic cancer, the contemporary use of surgery and systemic therapy in NETs, multidisciplinary approaches to hepatocellular carcinoma, and the evolving role of liver transplant and systemic therapy.

Black men with localized prostate cancer who had been treated with definitive radiotherapy had a lower likelihood of experiencing biochemical recurrence, distant metastasis, and prostate cancer–specific mortality compared with White men despite having more aggressive disease.

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

Ian E. Krop, MD, PhD, discusses highlights from 2021 in HER2-positive breast cancer and expectations for future research in 2022.

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

Sara Tolaney, MD, MPH, discusses the data with the oral selective estrogen receptor degrader, elacestrant, and the androgen receptor agonist, enobosarm, in estrogen receptor–positive, HER2-negative breast cancer.

Naresh Bumma, MD, discusses the focus of each presentation on frontline therapy, early and late relapse, and CAR T-cell therapy in multiple myeloma.

Jyoti D. Patel, MD, discusses biomarker testing, interpreting molecular result reports, and the growing armamentarium for patients with oncogene-driven lung cancer.